Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 1.Unmet Needs and Emerging Therapeutic Advances in Multiple Myeloma

EP: 2.Challenges in the Management of Relapsed/Refractory Multiple Myeloma

Now Viewing

EP: 3.Addressing Therapeutic Gaps in Multiple Myeloma with Bispecific Antibody Therapies

EP: 4.Bispecific Antibodies in Multiple Myeloma and Practical Definitions of Lines of Therapy

In this episode, experts describe how bispecific antibodies can help fill persistent therapeutic gaps in multiple myeloma. Panelists explain that these agents offer an important option for patients who lack access to cellular therapies or who are not ideal candidates for CAR T treatment. They discuss how bispecifics may fit into sequencing strategies, particularly for community practices already familiar with antibody drug conjugates. Experts also highlight that real world evidence continues to shape understanding of where bispecifics belong in the treatment pathway, including observations about responses after prior therapies and the role of bridging approaches. Safety considerations are outlined, with emphasis on cytokine release syndrome and neurotoxicity, and the importance of distinguishing these events from those typically associated with CAR T therapy. Panelists stress the need for practical pathways to manage predictable toxicities so that more patients can benefit from these emerging therapies.